Evidence map›Paper›PMID 33597950›Full record

ReviewFrontiers in immunology2020

A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.

Ainhoa Arana Echarri, Mark Beresford, John P Campbell, Robert H Jones, Rachel Butler, Kenneth J Gollob, Patricia C Brum, Dylan Thompson, James E Turner

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ainhoa Arana EcharriDepartment for Health, University of Bath, Bath, United Kingdom.
Mark BeresfordDepartment of Oncology and Haematology, Royal United Hospitals Bath NHS Trust, Bath, United Kingdom.
John P CampbellDepartment for Health, University of Bath, Bath, United Kingdom.
Robert H JonesDepartment of Medical Oncology, Velindre Cancer Centre, Cardiff, United Kingdom.
Rachel ButlerSouth West Genomics Laboratory Hub, North Bristol NHS Trust, Bristol, United Kingdom.
Kenneth J GollobInternational Center for Research, A.C.Camargo Cancer Center, São Paulo, Brazil.
Patricia C BrumSchool of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.
Dylan ThompsonDepartment for Health, University of Bath, Bath, United Kingdom.
James E TurnerDepartment for Health, University of Bath, Bath, United Kingdom.

Funding

Medical Research Council MR/N0137941/1
6 · The paper itself

Abstract

Breast cancer is the most common malignancy among women worldwide. Over the last four decades, diagnostic and therapeutic procedures have improved substantially, giving patients with localized disease a better chance of cure, and those with more advanced cancer, longer periods of disease control and survival. However, understanding and managing heterogeneity in the clinical response exhibited by patients remains a challenge. For some treatments, biomarkers are available to inform therapeutic options, assess pathological response and predict clinical outcomes. Nevertheless, some measurements are not employed universally and lack sensitivity and specificity, which might be influenced by tissue-specific alterations associated with aging and lifestyle. The first part of this article summarizes available and emerging biomarkers for clinical use, such as measurements that can be made in tumor biopsies or blood samples, including so-called liquid biopsies. The second part of this article outlines underappreciated factors that could influence the interpretation of these clinical measurements and affect treatment outcomes. For example, it has been shown that both adiposity and physical activity can modify the characteristics of tumors and surrounding tissues. In addition, evidence shows that inflammaging and immunosenescence interact with treatment and clinical outcomes and could be considered prognostic and predictive factors independently. In summary, changes to blood and tissues that reflect aging and patient characteristics, including lifestyle, are not commonly considered clinically or in research, either for practical reasons or because the supporting evidence base is developing. Thus, an aim of this article is to encourage an integrative phenomic approach in oncology research and clinical management.

Indexed as

AgingBiomarkers, TumorBreast NeoplasmsLife StyleFemaleGene Expression ProfilingHumansPhenomicsRisk FactorsTranscriptomeBiomarkers, Tumorbiomarkersbreast cancerclinical responseexerciseimmunosenescencelifestylephysical activitytumors

Identifiers

PMID33597950
PMCPMC7882710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.